Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.14
+1.8%
$1.37
$0.78
$2.48
$238.94M0.83.93 million shs2.01 million shs
Altimmune, Inc. stock logo
ALT
Altimmune
$7.49
-0.3%
$7.85
$2.09
$14.84
$532.47M0.112.65 million shs2.67 million shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$7.06
+5.1%
$6.98
$5.10
$16.84
$18.93M-1.9728,452 shs7,062 shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$1.35
+10.7%
$1.64
$1.02
$9.45
$8.03M1.260,582 shs125,574 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$62.27
+0.0%
$71.44
$8.28
$99.41
$6.87B1.052.90 million shs2.41 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+1.79%+3.64%-16.79%-28.75%+3.64%
Altimmune, Inc. stock logo
ALT
Altimmune
-0.27%+2.18%+2.60%-33.36%+75.82%
KALA BIO, Inc. stock logo
KALA
KALA BIO
+5.06%+8.45%+0.75%-4.85%-57.26%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
+10.66%+8.00%-19.16%-66.08%-80.96%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+0.02%-0.76%-19.10%-29.16%+179.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.8114 of 5 stars
3.53.00.04.03.20.00.6
Altimmune, Inc. stock logo
ALT
Altimmune
0.8686 of 5 stars
3.31.00.00.01.81.70.0
KALA BIO, Inc. stock logo
KALA
KALA BIO
4.4106 of 5 stars
3.55.00.04.42.51.70.6
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2.9193 of 5 stars
0.05.00.04.63.14.20.0
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3535 of 5 stars
4.62.00.04.72.12.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00
Buy$5.00338.60% Upside
Altimmune, Inc. stock logo
ALT
Altimmune
2.60
Moderate Buy$17.25130.31% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$16.50133.71% Upside
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.11
Buy$112.3880.46% Upside

Current Analyst Ratings

Latest AKBA, MTEM, VKTX, ALT, and KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/17/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $18.00
5/16/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$115.00 ➝ $116.00
5/16/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
5/14/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
5/10/2024
Altimmune, Inc. stock logo
ALT
Altimmune
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $24.00
4/29/2024
Altimmune, Inc. stock logo
ALT
Altimmune
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/25/2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
4/2/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $21.00
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/1/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00
3/28/2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $6.00
(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$194.62M1.23N/AN/A($0.16) per share-7.13
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,234.98N/AN/A$2.75 per share2.72
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M5.12N/AN/A$2.79 per share2.53
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$57.31M0.15N/AN/A$0.78 per share1.73
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$51.92M-$0.23N/AN/AN/A-22.99%N/A-18.01%8/23/2024 (Estimated)
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.59N/AN/AN/A-22,645.37%-46.96%-42.96%8/8/2024 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$42.20M-$15.15N/AN/AN/AN/A-366.43%-66.41%8/2/2024 (Estimated)
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$4.32N/AN/AN/A-57.92%-984.38%-56.85%8/8/2024 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$85.89M-$0.93N/AN/AN/AN/A-18.41%-17.69%7/24/2024 (Estimated)

Latest AKBA, MTEM, VKTX, ALT, and KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024Q1 2024
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A$0.08+$0.08$0.08N/A$11.09 million
5/9/2024Q1 2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.09-$0.09N/A-$0.09$41.13 million$32.61 million    
5/9/2024Q1 2024
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.36-$0.34+$0.02-$0.34N/A$0.01 million    
4/24/2024Q1 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.26+$0.01-$0.26N/AN/A    
3/29/2024Q4 2023
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A-$3.18-$3.18-$3.18N/AN/A
3/29/2024Q4 2023
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$2.10-$0.73+$1.37-$0.73N/A$7.02 million
3/27/2024Q4 2023
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.33+$0.02-$0.12N/A$0.04 million
3/14/2024Q4 2023
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.04-$0.04N/AN/A$55.64 million$56.20 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/A
1.70
1.31
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.55
16.55
KALA BIO, Inc. stock logo
KALA
KALA BIO
4.92
4.22
4.22
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.25
1.25
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
29.49
29.48

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
95.47%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.10%
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
KALA BIO, Inc. stock logo
KALA
KALA BIO
13.40%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
13.40%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
167209.60 million201.00 millionOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.90 million68.00 millionOptionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
432.82 million2.44 millionNot Optionable
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
626.58 million5.70 millionNo Data
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
28110.27 million105.09 millionOptionable

AKBA, MTEM, VKTX, ALT, and KALA Headlines

Recent News About These Companies

Viking Therapeutics (NASDAQ:VKTX) Upgraded by StockNews.com to Sell
2 Stocks That Could 10x by 2035

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Akebia Therapeutics logo

Akebia Therapeutics

NASDAQ:AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
KALA BIO logo

KALA BIO

NASDAQ:KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Molecular Templates logo

Molecular Templates

NASDAQ:MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Viking Therapeutics logo

Viking Therapeutics

NASDAQ:VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.